The combined treatment with chloroquine and the enzymatic oxidation products of spermine overcomes multidrug resistance of melanoma M14 ADR2 cells: A new therapeutic approach

Agostinelli,Enzo; Condello,Maria; Tempera,Giampiero; Macone,Alberto; Bozzuto,Giuseppina; Ohkubo,Shinji; Calcabrini,Annarica; Arancia,Giuseppe; Molinari,Agnese

doi:10.3892/ijo.2014.2502

The combined treatment with chloroquine and the enzymatic oxidation products of spermine overcomes multidrug resistance of melanoma M14 ADR2 cells: A new therapeutic approach

Authors:
- Enzo Agostinelli
- Maria Condello
- Giampiero Tempera
- Alberto Macone
- Giuseppina Bozzuto
- Shinji Ohkubo
- Annarica Calcabrini
- Giuseppe Arancia
- Agnese Molinari
View Affiliations

Affiliations: Istituto Pasteur-Fondazione Cenci Bolognetti and Department of Biochemical Sciences, Sapienza University of Rome and CNR, Ι-00185 Rome, Italy, Department of Technology and Health, Italian National Institute of Health, I-00161 Rome, Italy
Published online on: June 18, 2014 https://doi.org/10.3892/ijo.2014.2502
Pages: 1109-1122

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

It has been confirmed that multidrug resistant (MDR) melanoma cells (M14 ADR2) are more sensitive than their wild-type counterparts (M14 WT) to H2O2 and aldehydes, the products of bovine serum amine oxidase (BSAO)-catalyzed oxidation of spermine. The metabolites formed by BSAO and spermine are more toxic, in M14 cells, than exogenous H2O2 and acrolein, even though their concentration is lower during the initial phase of incubation due to their more gradual release than the exogenous products. Binding of BSAO to the cell membrane and release of the reaction products of spermine into the immediate vicinity of the cells, or directly into the cells, may explain the apparently paradoxical phenomenon. Both WT and MDR cells, after pre-treatment for 24 h, or longer, with the lysosomotropic compound chloroquine (CQ), show to be sensitized to subsequent exposure to BSAO/spermine enzymatic system. Evidence of ultrastructural aberrations and acridine orange release from lysosomes is presented in this study that is in favor of the permeabilization of the lysosomal membrane as the major cause of sensitization by CQ. Pre-treatment with CQ amplifies the ability of the metabolites formed from spermine by oxidative deamination to induce cell death. Melanocytes, differently from melanoma cells, were unaffected by the enzymatic system, even when preceded by CQ treatment. Since it is conceivable that combined treatment with a lysosomotropic compound and BSAO/spermine would be effective against tumour cells, it is of interest to search for such novel compounds, which might be promising for application in a therapeutic setting.

View Figures

View References

1	La Porta CA: Mechanism of drug sensitivity and resistance in melanoma. Curr Cancer Drug Targets. 3:391–397. 2009.PubMed/NCBI
2	Setia N, Abbas O, Sousa Y, Garb JL and Mahalingam M: Profiling of ABC transporters ABCB5, ABCF2 and nestin-positive stem cells in nevi, in situ and invasive melanoma. Mod Pathol. 25:1169–1175. 2012. View Article : Google Scholar : PubMed/NCBI
3	Davies MA: The role of the PI3K-AKT pathway in melanoma. Cancer J. 18:142–147. 2012. View Article : Google Scholar : PubMed/NCBI
4	Nikolaous VA, Stratigos AJ, Flaherty KT, et al: Melanoma: new insights and new therapies. J Invest Dermatol. 132:854–863. 2012. View Article : Google Scholar
5	Goodwin AC, Jadallah S, Toubaji A, Lecksell K, Hicks JL, Kowaski J, Bova GS, De Marzo AM, Netto GJ and Casero RA Jr: Increased spermine oxidase expression in human prostate cancer and prostatic intraepithelial neoplasia tissues. Prostate. 68:766–772. 2008. View Article : Google Scholar
6	Simoneau AR, Gerner EW, Nagle R, Ziogas A, Fujikawa-Brooks S, Yerushalmi H, Ahlering TE, Lieberman R, Mclaren CE, Anton-Culver H and Meyskens FL Jr: The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: results of a year-long phase IIb randomized placebo-controlled chemoprevention trial. Cancer Epidemiol Biomarkers Prev. 17:292–299. 2008.
7	Gerner EW and Meyskens FL: Polyamines and cancer: old molecules, new understanding. Nat Rev Cancer. 4:782–792. 2004. View Article : Google Scholar : PubMed/NCBI
8	Agostinelli E, Belli F, Molinari A, Condello M, Palmigiani P, Dalla Vedova L, Marra M, Seiler N and Arancia G: Toxicity of enzymatic oxidation products of spermine to human melanoma cells (M14): sensitization by heat and MDL 72527. Biochim Biophis Acta. 1763:1040–1050. 2006. View Article : Google Scholar : PubMed/NCBI
9	Agostinelli E, Condello M, Molinari A, Tempera G, Viceconte N and Arancia G: Cytotoxicity of spermine oxidation products to multidrug resistant melanoma cells (M14 ADR2): sensitisation by MDL 72527, a lysosomotropic compound. Int J Oncol. 35:485–498. 2009. View Article : Google Scholar
10	Marra M, Agostinelli E, Tempera G, Lombardi A, Meo G, Budillon A, Abbruzzese A, Giuberti G and Caraglia M: Anticancer drugs and hyperthermia enhance cytotoxicity induced by polyamine enzymatic oxidation products. Amino Acids. 33:273–281. 2007. View Article : Google Scholar
11	Marra M, Lombardi A, Agostinelli E, Giuberti G, Zappavigna S, Tempera G, Vitale G, Bifulco M, Abbruzzese A and Caraglia M: Bovine serum amine oxidase and spm potentiate docetaxel and interferon-alpha effects in inducing apoptosis on human cancer cells through the generation of oxidative stress. BBA-Mol Cell Res. 1783:2269–2278. 2008.
12	Agostinelli E, Dalla Vedova L, Belli F, Condello M, Arancia G and Seiler N: Sensitization of human colon adenocarcinoma cells (LoVo) to reactive oxygen species by lysosomotropic compounds. Int J Oncol. 29:947–955. 2006.PubMed/NCBI
13	Dai H, Kramer DL, Yang C, Murti KG, Porter CW and Cleveland JL: The polyamine oxidase inactivator MDL-72527 selectively induces apoptosis in transformed hematopoietic cells through lysosomotropic effects. Cancer Res. 59:4944–4954. 1999.
14	Iyamu E, Perdew H and Woods G: Growth inhibitory and differentiation effect of chloroquine and its analogue on human leukemic cells potentiate fetal hemoglobin production by targeting the polyamine pathway. Biochem Pharmacol. 77:1021–1029. 2009. View Article : Google Scholar
15	Turini P, Sabatini S, Befani O, Chimenti F, Casanova C, Riccio P and Mondovi B: Purification of serum amine oxidase. Anal Biochem. 125:294–298. 1982. View Article : Google Scholar
16	Janes SM, Mu D, Wemmer D, Smith AJ, Kaur S, Maltby D, Burlingam AL and Klinman JP: A new redox cofactor in eukaryotic enzymes: 6-Hydroxydopa at the active site of bovine serum amine oxidase. Science. 248:981–987. 1990. View Article : Google Scholar
17	Molinari A, Toccaceli L, Calcabrini A, Diociaiuti M, Cianfriglia M and Arancia G: Induction of P-glycoprotein expression on the plasma membrane of human melanoma cells. Anticancer Res. 20:2691–2696. 2000.PubMed/NCBI
18	Molinari A, Calcabrini A, Crateri P and Arancia G: Interaction of anthracyclin with cytoskeletal components of cultured carcinoma cells (CG5). Exp Mol Pathol. 53:11–33. 1990. View Article : Google Scholar : PubMed/NCBI
19	van Engeland M, Nieland LJ, Ramaekers FC, Schutte B and Reutelingsperger CP: Annexin V-affinity assay: a review on an apoptosis detection system based on phosphatidylserine exposure. Cytometry. 31:1–9. 1998.PubMed/NCBI
20	Nicoletti I, Migliorati G, Pagliacci MC, Grignani F and Riccardi C: A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods. 139:271–279. 1991. View Article : Google Scholar
21	Sharmin S, Sakata K, Kashiwagi K, Ueda S, Iwasaki S, Shirahata A and Igarashi K: Polyamine cytotoxicity in the presence of bovine serum amine oxidase. Biochem Biophys Res Commun. 282:228–235. 2001. View Article : Google Scholar : PubMed/NCBI
22	Calcabrini A, Arancia G, Marra M, Crateri P, Befani O, Martone A and Agostinelli E: Enzymatic oxidation products of spermine induce greater cytotoxic effects on human multidrug-resistant colon carcinoma cells (LoVo) than on their wild-type counterparts. Int J Cancer. 99:43–52. 2002. View Article : Google Scholar
23	Agostinelli E and Seiler N: Non-irradiation-derived reactive oxygen species (ROS) and cancer. Therapeutic implications. Amino Acids. 31:341–355. 2006. View Article : Google Scholar : PubMed/NCBI
24	Agostinelli E and Seiler N: Lysosomotropic compounds and spermine enzymatic oxidation products in cancer therapy (review). Int J Oncol. 31:473–484. 2007.PubMed/NCBI
25	Agostinelli E, Przybytkowskj E, Mondovì B and Averill-Bates DA: Heat enhancement of cytotoxicity induced by oxidation products of spermine in Chinese hamster ovary cells. Biochem Pharmacol. 72:36–42. 1994.PubMed/NCBI
26	Averill-Bates DA, Ke Q, Tanel A, Roy J, Fortier G and Agostinelli E: Mechanism of cell death induced by spermine and amine oxidase in mouse melanoma cells. Int J Oncol. 32:79–88. 2008.PubMed/NCBI
27	Lord-Fontaine S, Agostinelli E, Przybytkowskj E and Averill-Bates DA: Amine oxidase, spermine, and hyperthermia induce cytotoxicity in P-glycoprotein overexpressing multidrug resistant Chinese hamster ovary cells. Biochem Cell Biol. 79:165–175. 2001. View Article : Google Scholar
28	Averill-Bates DA, Cherif A, Agostinelli E, Tanel A and Fortier G: Anti-tumoral effect of native and immobilized bovine serum amine oxidase in a mouse melanoma model. Biochem Pharmacol. 69:1693–1704. 2005. View Article : Google Scholar : PubMed/NCBI
29	Demers N, Agostinelli E, Averill-Bates DA and Fortier G: Immobilization of native and poly(ethylene glycol)-treated (‘PEGylated’) bovine serum amine oxidase into a biocompatible hydrogel. Biotechnol Appl Biochem. 33:201–207. 2001.PubMed/NCBI
30	Gerner EW and Meyskens Fl Jr: Combination chemoprevention for colon cancer targeting polyamine synthesis and inflammation. Clin Cancer Res. 15:758–761. 2009. View Article : Google Scholar : PubMed/NCBI
31	Park BC, Park SH, Paek SH, et al: Chloroquine-induced nitric oxide increase and cell death is dependent on cellular GSH depletion in A172 human glioblastoma cells. Toxicol Lett. 178:52–60. 2008. View Article : Google Scholar
32	Jiang P, Zhao Y, Shi W, et al: Cell growth inhibition, G2/M cell cycle arrest, and apoptosis induced by Chloroquine in human breast cancer cell line Bcap-37. Cell Physiol Biochem. 22:431–440. 2008. View Article : Google Scholar : PubMed/NCBI
33	Kimura T, Yoshitsugu T, Atsushi T, et al: Chloroquine in cancer therapy: a double-edged sword of autophagy. Cancer Res. 73:3–7. 2013. View Article : Google Scholar : PubMed/NCBI
34	Michaud M, Martins I, Sukkurwala AQ, Adjemian S, Ma Y, Pellegatti P, et al: Autophagy-dependent anticancer immuneresponses induced by chemotherapeutic agents in mice. Science. 334:1573–1577. 2011. View Article : Google Scholar : PubMed/NCBI
35	Amaravadi RK and Thompson CB: The roles of therapy-induced autophagy and necrosis in cancer treatment. Clin Cancer Res. 13:7271–7279. 2007. View Article : Google Scholar : PubMed/NCBI
36	Tasdemir E, Galluzzi L, Maiuri MC, Criollo A, Vitale I, Hangen E, Modjtahedi N and Kroemer G: Methods for assessing autophagy and autophagic cell death. Methods Mol Biol. 445:29–76. 2008. View Article : Google Scholar : PubMed/NCBI
37	Vezmar M and Georges E: Reversal of MRP-mediated doxorubicin resistance with quinoline-based drugs. Biochem Pharmacol. 59:1245–1252. 2000. View Article : Google Scholar : PubMed/NCBI
38	Solomon VR and Lee H: Chloroquine and its analogs: a new promise of an old drug for effective and safe cancer therapies. Eur J Pharmacol. 625:220–233. 2009. View Article : Google Scholar : PubMed/NCBI
39	Homewood CA, Warhurst DC, Peters W and Baggaley VC: Lysosomes, pH and the anti-malarial action of chloroquine. Nature. 235:50–52. 1972. View Article : Google Scholar : PubMed/NCBI
40	Slater AF: Chloroquine: mechanism of drug action and resistance in Plasmodium falciparum. Pharmacol Ther. 57:203–235. 1993. View Article : Google Scholar : PubMed/NCBI
41	Agostinelli E, Tempera G, Dalla Vedova L, Condello M and Arancia G: MDL 72527 and spermine oxidation products induce a lysosomotropic effect and mitochondrial alterations on tumor cells. Biochem Soc Trans. 35:343–348. 2007. View Article : Google Scholar : PubMed/NCBI
42	Guicciardi ME, Leist M and Gores GJ: Lysosomes in cell death. Oncogene. 23:2881–2890. 2004. View Article : Google Scholar
43	Zhao M, Antunes F, Eaton JW and Brunk UT: Lysosomal enzymes promote mitochondrial oxidant production, cytochrome c release and apoptosis. Eur J Biochem. 270:13778–13786. 2003. View Article : Google Scholar : PubMed/NCBI
44	Yu Z, Li W and Brunk UT: 3-Aminopropanal is a lysosomotropic aldehyde that causes oxidative stress and apoptosis by rupturing lysosomes. APMIS. 111:643–652. 2003. View Article : Google Scholar : PubMed/NCBI
45	Zdolsek J, Zhang H, Roberg K and Brunk U: HO-mediated damage to lysosomal membranes of J-774 cells. Free Radic Res Commun. 18:71–85. 1993. View Article : Google Scholar : PubMed/NCBI
46	Gottesman MM and Pastan I: Biochemistry of multidrug resistance mediated by the multidrug transporter. Ann Rev Biochem. 62:385–342. 1993. View Article : Google Scholar : PubMed/NCBI
47	Arancia G, Calcabrini A, Marra M, Crateri P, Artico M, Martone A, Martelli F and Agostinelli E: Mitochondrial alterations induced by serum amine oxidase and spermine on human multidrug resistant tumor cells. Amino Acids. 26:273–282. 2004. View Article : Google Scholar : PubMed/NCBI
48	Fehrenbacher N, Gyrd-Hansen M, Poulsen B, Felbor U, Kallunki T, Boes M, Weber E, Leist M and Jäättelä M: Sensitization to the lysosomal cell death pathway upon immortalization and transformation. Cancer Res. 64:5301–5310. 2004. View Article : Google Scholar : PubMed/NCBI
49	Fehrenbacher N and Jäättelä M: Lysosomes as targets for cancer therapy. Cancer Res. 65:2993–2995. 2005.PubMed/NCBI
50	Savarino A, Lucia MB, Giordano F and Cauda R: Risks and benefits of chloroquine use in anticancer strategies. Lancet Oncol. 7:792–793. 2006. View Article : Google Scholar : PubMed/NCBI
51	Briceño E, Reyes S and Sotelo J: Therapy of glioblastoma multiforme improved by the antimutagenic chloroquine. Neurosurg Focus. 14:e32003.PubMed/NCBI